Core Viewpoint - Opus Genetics, Inc. is urging stockholders to vote for its nine nominated directors on the BLUE proxy card, emphasizing the importance of the upcoming Annual Meeting on April 30, 2025, as a pivotal moment for the company's transformation and future success [2][3][15] Company Strategy and Transformation - The company has undergone significant changes over the past two years, including a strategic repositioning after facing challenges with its previous assets [4][5] - In 2023, the board terminated the former CEO and appointed Dr. George Magrath as the new CEO, who has since built a strong executive team [5][11] - A review of the company's assets led to the acquisition of Legacy Opus, which has a promising pipeline of gene therapies for inherited retinal diseases [6][9] Board of Directors and Governance - The board is nominating nine candidates for election, including three new directors with extensive experience in biotechnology and clinical development [10][11] - The board believes that the election of the former CEO's nominees would not serve the best interests of stockholders and could reverse the company's progress [13][14] Financial Support and Market Confidence - The company recently raised $21.5 million from top-tier healthcare investors, indicating strong market confidence in its new strategy and leadership [12]
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress